OXiGENE Announces Interim Phase 2 Data for Lead Clinical Candidate CA4P (fosbretabulin) in Neuroendocrine Tumors
-- Biomarker results in first nine subjects add to CA4P evidence of activity -- -- Full results are expected in the second half of 2016 -- SOUTH SAN FRANCISCO, Calif., Oct. 19, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical …